Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Caterina Bissantz

Mark Rogers-Evans

Hasane Ratni

Christophe Grundschober

Patrick Schnider

Raffaello Masciadri

Matthias Heinrich Nettekoven

Hans G Richter

Rainer Eugen Martin

Henrietta Dehmlow

Ulrike Obst Sander

Christoph Ullmer

Uwe Grether

Stephan Roever

Shawn David Erickson

Kyungjin Kim

Sherrie Lynn Pietranico-Cole

Henner Knust

Atsushi Kimbara

Philippe Jablonski

Patrizio Mattei

Claus Riemer

Roland Jakob-Roetne

Paul Hebeisen

Konrad H Bleicher

Erwin Goetschi

Jean-Michel Adam

Prabha Saba Karnachi

Emmanuel Pinard

Zhiwei Wang

Bernd Buettelmann

Jean-Marc Plancher

Torsten Hoffmann

Anja Limberg

Tanja Schulz-Gasch

Markus Rudolph

Christian D Lerner

Walter Vifian

Andreas Koblet

Xihan Wu

Marco Prunotto

Angelique Patiny-Adam

Qingping Liu

Baledi Dhurwasulu

Anindya Hazra

Wulun Yang

Christoph Ulmer

René Bonnafous

Matthias Nettekoven

Christian Lerner

Atushi Kimbara

This invention relates to novel 3-aminopyridines of the formula wherein B, Band Rto Rare as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

3-amino-pyridines as GPBAR1 agonists

The present compounds compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.

Peptides as oxytocin agonists

The invention relates to compounds of formula wherein variables are defined herein. It has been found that the present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrom.

The invention relates to the use of a compound of formula I wherein

Oxytocin receptor agonists for the treatment of CNS diseases

The present invention relates to compounds of formula wherein the substituents are described in claimand to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.

COMT inhibitors

The invention relates to a compound of formula (I) wherein Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament. In particular, the compound may be used as a preferential agonist of Cannabinoid Receptor 2.

Pyrazine derivatives

The invention relates to a compound of formula (I)  Wherein R, R, Rand Rare defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.

Pyridine derivatives as agonists of the CB2 receptor

The invention relates to a compound of formula (I) wherein A and Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

[1,2,3]triazolo[4,5-D]pyrimidine derivatives

The invention relates to a compound of formula (I) wherein A, Rand Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

This invention relates to novel 3-aminopyridines of the formula 

This invention relates to novel 1-hydroxyimino-3-phenyl-propanes of the formula wherein Rto Rare as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may be used as medicaments for the treatment of diseases such as type II diabetes.

1-hydroxyimino-3-phenyl-propanes

This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula wherein A, A, B, Band Rto Rare as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds

The present invention is concerned with spiro-dihydrotetraazabenzoazulenes, i.e. spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes of formula I wherein R, R, R, X, Y, Z, m and n are as described herein. The compounds according to the invention act as V1a receptor modulators and are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes

Growing community of inventors

Village-Neuf, France

Caterina Bissantz